Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dacomitinib in EGFR-mutated NSCLC with brain metastases
NCT04339829Phase 2Unknown
- Sponsor
- Guangdong Association of Clinical Trials
- Start
- Aug 2020
- Primary completion
- Jul 2022
- Modality
- Fragment-Derived Small Molecules, Allosteric Modulators, Orthosteric Ligands
01
Overview
A Phase 2 trial of dacomitinib in non-small cell lung cancer (NSCLC), sponsored by Guangdong Association of Clinical Trials. Status: unknown.
02
Drugs
dacomitinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT04339829.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04339829.